A team of investigators from the Technion Faculty of Chemical Engineering, including the graduate students Ofri Vizenblit and Rawan Mhajne and led by Dr. Assaf Zinger, developed a novel nanoparticle-based immunotherapy that suppresses tumor growth in triple-negative breast cancer (TNBC) without delivering drugs or directly targeting cancer cells
bringing together leading clinicians from Rambam Health Care Campus and researchers from the Technion. This focused event is designed to foster meaningful dialogue at the interface of neuroscience, engineering, and clinical practice, with an emphasis on advancing innovative, patient-oriented solutions.